Tagged Articles

obesity 43 articles

FDA approves new diet pill Contrave

A new prescription diet pill has been given clearance by the Food and Drug Administration (FDA) for marketing in the United States. Contrave, made by Orexigen Therapeutics, is a combination of bupropion, an antidepressant that is also used for smoking cessation, and naltrexone, a drug used to treat drug and alcohol dependence. Contrave is approved for overweight or obese patients with a body mass index (BMI) of 30 or higher, as well as people with a BMI of 27 or higher with at least one other health issue such as diabetes. Patients treated with Contrave lost an average of 4.2 ... Read More

FDA panel recommends approving diabetes treatment for obese patients

A Food and Drug Administration (FDA) advisory panel has given a thumbs-up recommendation to Novo Nordisk’s type 2 diabetes drug liraglutide for the treatment of chronic obesity in patients with at least one weight-related health issue, such as hypertension or pre-diabetes. Liraglutide, known commercially as Victoza, would be sold under the label Saxenda for the obesity indication if it is approved by the FDA. The agency is not required to follow the recommendations of its advisory panels, but it usually does. The positive recommendation was based on a clinical trial in which patients were given 3 mg of liraglutide. About ... Read More

New testosterone treatment in development carries fewer side effects

Testosterone levels in men typically drop as a man ages, but when it drops too low it signals a possible problem. In many cases the drop can be associated with obesity, diabetes and circulatory disease. Low testosterone levels can result in symptoms such as low libido, loss of muscle mass, increased body fat, and depression. Regardless the cause, many doctors prescribe testosterone replacement therapies, such as AndroGel, Axiron and Testim, to treat the condition. However, recent studies have shown that testosterone therapy can increase the risk of heart attack, stroke or death. The drugs can also be expensive, and after ... Read More

Insulin therapy may help prevent acute pancreatitis

Acute pancreatitis affects about 20,000 people every year and results in 1,000 deaths. It can also increase the risk for pancreatic cancer, one of the most deadly forms of the disease. Yet, there is no immediate cure for the painful and debilitating condition and treatment is restricted to intravenous fluid and nutritional support. But a team of researchers from the Faculty of Life Sciences say that insulin could possibly help ease the symptoms of acute pancreatitis. Pancreatitis is a condition in which the pancreas essentially digests itself, causing severe abdominal pain, vomiting and systemic inflammation. The major cause of pancreatitis includes ... Read More

Pancreatic cancer research grows as cases of the disease increase

Several organizations and philanthropies are banding together to find more effective treatments for pancreatic cancer, one of the most deadly forms of the disease. Entertainment industry’s Stand Up to Cancer (SU2C) initiative, family philanthropies, the advocacy group Pancreatic Cancer Action Network (PanCan), and the PanCan-inspired federal “recalcitrant cancer” law are making it possible for medical centers to test chemotherapies, targeted therapies, immunotherapies and other treatments for pancreatic cancer patients. Pancreatic cancer has a 6 percent five-year survival rate and is the fourth leading cause of cancer related-deaths. However, cases of the disease are growing, and experts say the disease will ... Read More

Study: Children exposed to SSRIs in utero at greater risk for obesity, type 2 diabetes

Babies born to women who took antidepressants while pregnant are more likely to become obese and develop type 2 diabetes, according to a new study. Obesity and type 2 diabetes in children is already on the rise in the United States and is generally blamed on poor diets and reduced physical activity. However, researchers with McMaster University say that maternal antidepressant use may also be a contributing factor in the pediatric obesity and diabetes epidemic. The study focused on a commonly prescribed type of antidepressant known as selective serotonin reuptake inhibitors, or SSRIs, which include the brand names Prozac, Lexapro, ... Read More

Type 2 diabetes drug Victoza tested as potential diet drug

The type 2 diabetes drug Victoza (liraglutide) can help overweight and obese people without diabetes lose weight, according to a new multinational clinical trial, but the drug comes with some risks. Victoza, an injectable drug in a class of diabetes medications known as glucagonlike peptide-1 (GLP-1) agonist, was approved by the Food and Drug Administration (FDA) in January 2010 to help lower blood sugar levels in people with type 2 diabetes. In an effort to expand the indication to non-diabetics who are overweight, the medication was pitted against a placebo and the currently marketed anti-obesity drug Qsymia, a combination of ... Read More

Extra weight carries no health benefit for diabetics

Think those few extra pounds might help you get through sickness? Think again. A new study shows they actually do more harm that good. “We don’t see any positive effect at all,” Deirdre Tobias, with the Harvard School of Public Health told Bloomberg. The bottom line is that being overweight increases your likelihood of heart disease, cancer and premature death. About two-thirds of U.S. adults are overweight, and a third of them are obese. Many of those who are overweight also have type 2 diabetes, a condition in which the body does not produce enough insulin to regulate blood sugar ... Read More

FDA approves new type 2 diabetes medication Farxiga

A new drug has been approved by the Food and Drug Administration (FDA) to help regulate blood sugar in patients with type 2 diabetes. Farxiga, developed by AstraZeneca and Bristol-Myers Squibb, has been available in Europe under the name Forxiga. U.S. drug regulators rejected the drug last year because of bladder cancer, heart disease and liver toxicity concerns. Farxiga is the second in a class of drugs known as SGLT2 inhibitors to be approved in the United States. Johnson & Johnson’s Invokana was approved earlier this year. Other drugmakers, including Boehringer Ingelheim, are also developing SGLT2 inhibitors. Drugs in this class ... Read More

Experts caution against statin use to lower breast cancer risk

A new study has linked high cholesterol to an increased risk of breast cancer, prompting researchers to question whether cholesterol-lowering statins could help prevent cancer. However, cancer charities cautioned that it is too soon to advise women to take statins as a preventative measure for breast cancer. Previous research has already linked obesity to an increased risk of breast and bowel cancer as well as cancers of the uterus. Fat can cause the body to excrete hormones such as estrogen, which fuels cancer growth. Researchers with Duke University Medical Center, using laboratory mice, found that cholesterol has a similar effect. ... Read More